Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25277592 | 0.81 | — | — | |
| SCHEMBL8708682 | 0.78 | EPHX1 (0.32) | — | |
| SCHEMBL596312 | 0.77 | — | — | |
| SCHEMBL25270404 | 0.77 | — | — | |
| SCHEMBL19321811 | 0.75 | CYP2C9 (0.41) | — | |
| SCHEMBL19321824 | 0.75 | CHRM2 (0.31) | — | |
| SCHEMBL30631342 | 0.74 | TSHR (0.30) | — | |
| SCHEMBL579902 | 0.73 | OPRM1 (0.35) | — | |
| SCHEMBL595093 | 0.73 | ALDH1A1 (0.33) | — | |
| SCHEMBL176374 | 0.73 | ALDH1A1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3197507-A1 | MALODOR REDUCTION COMPOSITIONS | The Procter and Gamble Company (US) | 2017-08-02 | — | — | EP | claimed |
| WO-2016049389-A1 | MALODOR REDUCTION COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2016-03-31 | — | — | WO | claimed |
| JP-7330668-A | — | — | None | — | — | JP | disclosed |
| US-20230295115-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2023-09-21 | — | — | US | disclosed |
| CN-113929866-B | Modified resin and resin composition | 旭化成株式会社 | 2023-07-07 | — | — | CN | disclosed |
| US-11634659-B2 | Fragrances with rose scent | SYMRISE AG (DE) | 2023-04-25 | — | — | US | disclosed |
| CN-111205424-B | Modified resin and resin composition | 旭化成株式会社 | 2022-04-08 | — | — | CN | disclosed |
| CN-113929866-A | Modified resin and resin composition | 旭化成株式会社 | 2022-01-14 | — | — | CN | disclosed |
| US-20210324300-A1 | NOVEL FRAGRANCES WITH ROSE SCENT | SYMRISE AG (DE) | 2021-10-21 | — | — | US | disclosed |
| CN-107629183-B | Modified resin and resin composition | 旭化成株式会社 | 2021-01-05 | — | — | CN | disclosed |
| CN-111205424-A | Modified resin and resin composition | 旭化成株式会社 | 2020-05-29 | — | — | CN | disclosed |
| CN-106278999-B | S1P regulator | 比奥根MA公司 | 2019-10-25 | — | — | CN | disclosed |
| CN-105358602-B | modified resin and resin composition | 旭化成株式会社 | 2018-12-04 | — | — | CN | disclosed |
| CN-107629183-A | Modified resin and resin combination | 旭化成株式会社 | 2018-01-26 | — | — | CN | disclosed |
| EP-2364088-B1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC INC (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8546359-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN IDEC MA INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20130059821-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC. | 2013-03-07 | — | — | US | disclosed |
| US-8269043-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN IDEC MA INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20100160258-A1 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN IDEC MA INC. (US) | 2010-06-24 | — | — | US | disclosed |
| JP-H07330668-A | NEW ALKYL-SUBSTITUTED CYCLOHEXYL ESTER OF BRANCHED ALIPHATIC CARBOXYLIC ACID AND PRODUCTION THEREOF | MARUZEN PETROCHEM CO LTD | 1995-12-19 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634659-B2 | Fragrances with rose scent | NR1H2, DUOX2, AOX1 | ADORA3 4193/4885 |
| US-20100160258-A1 | Bicyclic aryl sphingosine 1-phosphate analogs | S1PR1, S1PR3, S1PR4 | ADORA3 544/4885 |
| US-20130059821-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR2, S1PR3 | ADORA3 1100/4885 |
| US-20210324300-A1 | NOVEL FRAGRANCES WITH ROSE SCENT | NR1H2, DUOX2, AOX1 | ADORA3 4343/4885 |
| US-20230295115-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | HCCS, HAVCR2, HDGF | ADORA3 2424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.